Literature DB >> 14673052

Are older cancer patients being referred to oncologists? A mail questionnaire of Ontario primary care practitioners to evaluate their referral patterns.

Carol A Townsley1, Kendra Naidoo, Gregory R Pond, Wendy Melnick, Sharon E Straus, Lillian L Siu.   

Abstract

PURPOSE: Understanding why older patients are frequently underrepresented in cancer services use and clinical research may help to increase their participation in clinical trials and eventually result in better cancer care for this vulnerable population.
METHODS: To identify potential barriers that may prevent older cancer patients from being referred from a primary care physician (PCP) to an oncology specialist, a self-administered questionnaire was mailed to 9,312 PCPs throughout Ontario.
RESULTS: With a one-time mailing, 2,240 questionnaires were returned (response rate, 24%) of which 2,089 (93%) were assessable. Although 86% of respondents would refer most older patients with early-stage, potentially curable cancers to oncologists, only 65% would refer those with advanced-stage, potentially incurable cancers. The factors that most influence referral decisions of PCPs are patient's desire to be referred (69%), type (54%) and stage (49%) of cancer, and severity of cancer symptoms (49%). Other factors including age do not seem to influence the referral decision. Approximately 9% of respondents found it difficult to refer older cancer patients to oncology specialists, with the most commonly cited barriers being the length of waiting lists, mandatory tissue diagnosis before referral, and the belief that oncologists seldom relate to PCPs.
CONCLUSION: Most PCPs stated that they would refer all elderly patients with cancer to oncologists and that referral decisions were based mainly on patients' wishes. Continued efforts are needed to overcome barriers in the referral process and to understand the perspectives of elderly patients to enhance their cancer care.

Entities:  

Mesh:

Year:  2003        PMID: 14673052     DOI: 10.1200/JCO.2003.06.073

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Family physicians' satisfaction with current practice: what is the role of their interactions with specialists?

Authors:  Amardeep Thind; Tom Freeman; Cathy Thorpe; Andrea Burt; Moira Stewart
Journal:  Healthc Policy       Date:  2009-02

2.  The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist.

Authors:  Ruili Luo; Sharon H Giordano; Dong D Zhang; Jean Freeman; James S Goodwin
Journal:  Cancer       Date:  2007-03-01       Impact factor: 6.860

3.  Factors influencing general practitioners in the referral of elderly cancer patients.

Authors:  Fleur Delva; Emilie Marien; Marianne Fonck; Muriel Rainfray; Jean-Louis Demeaux; Philippe Moreaud; Pierre Soubeyran; Annie J Sasco; Simone Mathoulin-Pélissier
Journal:  BMC Cancer       Date:  2011-01-06       Impact factor: 4.430

Review 4.  Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment.

Authors:  Schroder Sattar; Shabbir M H Alibhai; Sandra L Spoelstra; Rouhi Fazelzad; Martine T E Puts
Journal:  Support Care Cancer       Date:  2016-07-22       Impact factor: 3.603

Review 5.  Management of elderly patients with primary central nervous system lymphoma.

Authors:  Mariza Daras; Lisa M DeAngelis
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 5.081

6.  Access granted! barriers endure: determinants of difficulties accessing specialist care when required in Ontario, Canada.

Authors:  Daniel W Harrington; Kathi Wilson; Mark Rosenberg; Scott Bell
Journal:  BMC Health Serv Res       Date:  2013-04-22       Impact factor: 2.655

7.  Understanding the attitudes of the elderly towards enrolment into cancer clinical trials.

Authors:  Carol A Townsley; Kelvin K Chan; Gregory R Pond; Christine Marquez; Lillian L Siu; Sharon E Straus
Journal:  BMC Cancer       Date:  2006-02-08       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.